Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984347 | 1.00 | CNR1 (0.66) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL4826179 | 0.99 | CNR1 (0.65) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL4986242 | 0.99 | CNR1 (0.65) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3372130 | 0.99 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL22245053 | 0.88 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL3370445 | 0.87 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL10098345 | 0.87 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL3475482 | 0.87 | CNR1 (0.66) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3475668 | 0.84 | SLC6A4 (0.49) | CNR1CNR2 | |
| SCHEMBL200500 | 0.83 | SLC6A2 (0.56) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2023089612-A1 | PERIPHERAL CB1 RECEPTOR ANTAGONISTS FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-05-25 | — | — | WO | disclosed |
| US-20220119365-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| WO-2020148760-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-07-23 | — | — | WO | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088926-B2 | Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088926-B2 | Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088926-B2 | Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-20 | — | — | US | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| CN-1956949-A | Substituted sulfonamides | MERCK & CO INC (US) | 2007-05-02 | — | — | CN | disclosed |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| CN-1871208-A | Arylalkyl amines as cannabinoid receptor modulators | MERCK & CO INC (US) | 2006-11-29 | — | — | CN | disclosed |
| CN-1639112-A | Substituted amides having cannabinoid-1 receptor activity | MERCK & CO INC (US) | 2005-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885 |
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885 |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | CNR2, CNR1, CHRNA4 | CNR1 2/4885CNR2 1/4885 |
| US-20220119365-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | CNR1, CNR2, HCRTR1 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.